|
|
- 2019
Effects of Evolocumab on the ApoA1 Remnant Ratio: A Pooled Analysis of Phase 3 StudiesDOI: 10.1007/s40119-019-0133-6 Keywords: Evolocumab, Mixed dyslipidemia, Non-HDL-C, PCSK9, Remnant lipoprotein, Threshold, VLDL Abstract: The online version of this article (10.1007/s40119-019-0133-6) contains supplementary material, which is available to authorized users
|
